We are pleased to announce that, as of May 10, 2016, the 3000th trial participant has been randomized! We have come a long way, and we are grateful to the participants and to you for your sustained efforts and dedication to the trial. There is still much work to do but we wanted to take this opportunity to thank you and celebrate this important milestone.
What is the ISCHEMIA Study?
- An international comparative effectiveness study
- The purpose of ISCHEMIA is to determine the best way to manage stable ischemic heart disease
- Patients with moderate or severe ischemia on stress test imaging may be eligible for participation
If you are a physician and would like more information, please visit the For Physicians section. If you are a patient and would like to learn more about the ISCHEMIA study, please e-mail email@example.com
Why is the ISCHEMIA Study Important?
Ischemic heart disease (IHD) is the leading cause of death and disability worldwide and affects 17,600,000 Americans, resulting in about 450,000 deaths in the United States annually. Globally, 7.2 million deaths are caused by IHD each year.
Medical therapy (medication and lifestyle changes) should always be used to treat IHD. Many doctors routinely use an invasive approach in addition to medical therapy to treat IHD; however, it is not known if this approach is better than medical therapy alone as the initial treatment of patients with stable ischemic heart disease (SIHD). ISCHEMIA is designed to find the answer. Click here to learn more about the ISCHEMIA study.
ISCHEMIA Enrollment Updates
ISCHEMIA Enrollment Updates
As of October 25th 2016, there are 3,499 participants (pts) randomized worldwide in the ISCHEMIA study. Click here to see the randomizations by country.
Congratulations To Our Top Sites!
|Site name||Region||Study Team||Rand Rate & Total Rands|
|Government Medical College||India||PI: Dr. Sajeev, Dr. Rajesh & Dr. Kumar SC: Anand, Bijith, Ravindran & Sajeev||4.0 pts/mth, 144 pts|
|Heart Instituto do Coracao - University of Sao Paulo||Brazil||PI: Dr. Hueb SC: Takiuti & Borges Miyamoto Girardi||3.5 pts/mth, 94 pts|
|Northwick Park Hospital-Royal Brompton Hospital||UK||PI: Prof. Senior SC: Kinsey, Collins, Gurunathan, Hassan, Howard, Kavalakkat & Evans||3.4 pts/mth, 147 pts|
|Sri Jayadeva Institute of Cardiovascular Sciences and Research||India||PI: Dr. Manjunath & Dr. Moorthy SC: Nataraj & Murthy||2.8 pts/mth, 94 pts|
|Atlanta V.A. Medical Center||USA||PI: Dr. Mavromatis SC: Montazeri, Lee & Patel||2.5 pts/mth, 92 pts|
|Coronary and Structural Heart Diseases Department, Institute of Cardiology||Poland||PI: Prof. Demkow SC: Chojnacka, Frelek & Pracon||2.3 pts/mth, 102 pts|
|Hospital Universitario La Paz||Spain||PI: Dr. Lopez Sendon SC: Valbuena, Castro, La Paz Mediavilla, Valbuena & Fernandez-Figar||2.2 pts/ mth, 84 pts|
|Bakulev Scientific Center for Cardiovascular Surgery||Russia||Dr. L. Bockeria SC: O. Bockeria, & Kudzoeva||2.1 pts/mth, 79 pts|
|Ram Manohar Lohia Hospital||India||PI: Dr. Pandit SC: Bajaj, Pandit & Yadav||1.8 pts/mth, 66 pts|
|Montreal Heart Institute||Canada||PI: Gosselin SC: Vat & Proietti||1.4 pts/mth, 66 pts|